Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) is one of 72 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare Guided Therapeutics to similar businesses based on the strength of its risk, analyst recommendations, valuation, dividends, institutional ownership, earnings and profitability.
Volatility & Risk
Guided Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 1.00, meaning that their average stock price is 0% more volatile than the S&P 500.
Institutional & Insider Ownership
9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by company insiders. Comparatively, 15.0% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
Gross Revenue | Net Income | Price/Earnings Ratio | |
Guided Therapeutics | $100,000.00 | -$3.49 million | -4.67 |
Guided Therapeutics Competitors | $1.04 billion | $87.41 million | -8.54 |
Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Guided Therapeutics | N/A | N/A | -138.23% |
Guided Therapeutics Competitors | -334.12% | -44.43% | -23.67% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Guided Therapeutics and its peers, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Guided Therapeutics | 0 | 0 | 0 | 0 | N/A |
Guided Therapeutics Competitors | 264 | 797 | 1995 | 108 | 2.62 |
As a group, “Electromedical equipment” companies have a potential upside of 3,053.82%. Given Guided Therapeutics’ peers higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its peers.
Summary
Guided Therapeutics peers beat Guided Therapeutics on 6 of the 10 factors compared.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.